Mineralys Therapeutics, Inc. (MLYS)

Market Cap	2.50B +30.6%
Revenue (ttm)	n/a
Net Income	-349.58M
EPS	-4.38
Shares Out	88.41M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,325,735
Open	29.15
Previous Close	29.04
Day's Range	27.72 - 29.40
52-Week Range	22.30 - 47.65
Beta	0.67
Analysts	Strong Buy
Price Target	48.50 (+71.56%)
Earnings Date	Aug 11, 2026

About MLYS

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Minera...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 10, 2023
• Employees: 76
• Stock Exchange: NASDAQ
• Ticker Symbol: MLYS
• Website: https://mineralystx.com

Analyst Summary

According to 10 analysts, the average rating for MLYS stock is "Strong Buy." The 12-month stock price target is $48.5, which is an increase of 71.56% from the latest price.

Price Target

$48.5

(71.56% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Sep 4, 2026

Data Sources Report a data error